Investment Thesis
Aprea Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and no near-term revenue generation, having consumed $12.9M in operating cash flow with only $14.6M in cash remaining. The company faces an acute liquidity crisis as current cash reserves provide less than 14 months of runway at current burn rates, with no clear path to profitability or revenue generation visible in the financial statements.
APRE Strengths
- Strong immediate liquidity position with $14.6M cash and 5.63x current ratio
- Minimal debt burden with zero long-term debt and 0.0x debt/equity ratio
- Recent insider activity with 4 Form 4 filings in last 90 days indicating some management engagement
APRE Risks
- No revenue generation with operating losses of -$13.2M and negative operating margin indicating early-stage pre-commercial status
- Severe cash burn rate of -$12.9M in operating cash flow with less than 14 months of cash runway at current rates
- Negative returns on equity (-101.3%) and assets (-79.1%) demonstrate value destruction with no visible path to profitability
- Pre-revenue pharmaceutical company faces extremely high clinical development and regulatory approval risk with unclear pipeline maturity
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway
- Clinical trial progress and regulatory milestone announcements
- Capital raising activities and dilution impact on existing shareholders
APRE Financial Metrics
APRE Profitability Ratios
APRE Balance Sheet & Liquidity
APRE 5-Year Financial Trend
5-Year Trend Summary: Aprea Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.35 indicates the company is currently unprofitable.
APRE Growth Metrics (YoY)
APRE Capital Allocation
APRE SEC Filings
Access official SEC EDGAR filings for Aprea Therapeutics, Inc. (CIK: 0001781983)